Evidence map›Paper›PMID 35836935›Full record

ArticleFrontiers in molecular biosciences2022

Molecular Modeling of ABHD5 Structure and Ligand Recognition.

Rezvan Shahoei, Susheel Pangeni, Matthew A Sanders, Huamei Zhang, Ljiljana Mladenovic-Lucas, William R Roush, Geoff Halvorsen, Christopher V Kelly, James G Granneman, Yu-Ming M Huang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Unraveling the Molecular Mechanisms of ABHD5 Membrane Targeting.bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rezvan ShahoeiDepartment of Physics and Astronomy, Wayne State University, Detroit, MI, United States.
Susheel PangeniDepartment of Physics and Astronomy, Wayne State University, Detroit, MI, United States.
Matthew A SandersCenter for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI, United States.
Huamei ZhangCenter for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI, United States.
Ljiljana Mladenovic-LucasCenter for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI, United States.
William R RoushDepartment of Chemistry, Scripps Florida, Jupiter, FL, United States.
Geoff HalvorsenDepartment of Chemistry, Scripps Florida, Jupiter, FL, United States.
Christopher V KellyDepartment of Physics and Astronomy, Wayne State University, Detroit, MI, United States.
James G GrannemanCenter for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI, United States.
Yu-Ming M HuangDepartment of Physics and Astronomy, Wayne State University, Detroit, MI, United States.
Wayne State University · USScripps (United States) · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Analysis of Lipolytic Trafficking in Adipocytes.R01DK076629 · NIDDK · WAYNE STATE UNIVERSITY · PI James G Granneman, Christopher V Kelly · 2009 to 2026
$7.1M
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK076629
6 · The paper itself

Abstract

Alpha/beta hydrolase domain-containing 5 (ABHD5), also termed CGI-58, is the key upstream activator of adipose triglyceride lipase (ATGL), which plays an essential role in lipid metabolism and energy storage. Mutations in ABHD5 disrupt lipolysis and are known to cause the Chanarin-Dorfman syndrome. Despite its importance, the structure of ABHD5 remains unknown. In this work, we combine computational and experimental methods to build a 3D structure of ABHD5. Multiple comparative and machine learning-based homology modeling methods are used to obtain possible models of ABHD5. The results from Gaussian accelerated molecular dynamics and experimental data of the apo models and their mutants are used to select the most likely model. Moreover, ensemble docking is performed on representative conformations of ABHD5 to reveal the binding mechanism of ABHD5 and a series of synthetic ligands. Our study suggests that the ABHD5 models created by deep learning-based methods are the best candidate structures for the ABHD5 protein. The mutations of E41, R116, and G328 disturb the hydrogen bonding network with nearby residues and suppress membrane targeting or ATGL activation. The simulations also reveal that the hydrophobic interactions are responsible for binding sulfonyl piperazine ligands to ABHD5. Our work provides fundamental insight into the structure of ABHD5 and its ligand-binding mode, which can be further applied to develop ABHD5 as a therapeutic target for metabolic disease and cancer.

Indexed as

ABHD5AlphaFolddockingligand bindinglipid dropletmolecular dynamicsprotein mutationstructural modeling

Identifiers

PMID35836935
PMCPMC9274090
OpenAlexW4283651323

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.